Navigation Links
Genzyme Launches Cholestagel(R) in Europe
Date:10/23/2007

used on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

This press release contains forward-looking statements, including statements about the timing and geographies of Cholestagel's launch, as well as statements concerning Genzyme's plans to seek regulatory approval for Cholestagel in additional geographies. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others, the size of the market for the therapy in any particular geography, the sufficiency of reimbursement for the therapy in any particular geography; actions by governmental authorities related to Cholestagel, and the other risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the quarter ending June 30, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise the statements.

Genzyme(R) and Cholestagel(R) are registered trademarks of Genzyme Corporation and WelChol(R) is a registered trademark of Daiichi Sankyo Inc. All rights reserved.

Genzyme's press releases and other company information are available at http://www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

Media Contact: Investor Co
'/>"/>

SOURCE Genzyme Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cytochroma settles lawsuit with Genzyme
2. Genzyme sues former Bone Care employees
3. Genzyme acquistion of Bone Care approved, significant impact forecast
4. Merge launches diagnostic mammography workstation in Europe
5. Einstein Wireless launches cellular alert system
6. Logistics Health launches compliance management tool
7. UW-Madison launches new high-speed research network
8. UWM launches research foundation
9. TeraMedica launches information manager
10. GE Healthcare launches hybrid electronic record
11. Cedara launches new version of DICOM toolkit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, ... announce the relaunch of his highly informative blog, now named ... “ What are Stem Cells ?” Dr. Harman’s purpose ... in the basics of stem cell therapy so that pet ... of treatment when considering regenerative medicine. , A veterinarian by ...
(Date:7/10/2014)... PETERSBURG, Russia , July 10, 2014 ... Russian Federation Dmitry Medvedev , presented ... biopharmaceutical company BIOCAD . The Company is developing ... scope of MabNext project BIOCAD develops a number of ... cancer and autoimmune diseases. The ceremony took place at ...
(Date:7/10/2014)... 2014 -- According to the International Atomic Energy ... comes from terrorists acquiring sufficient quantities of plutonium ... crude nuclear explosive device. The IAEA also notes ... involved gram-level quantities, which can be challenging to ... a new study appearing this week in the ...
(Date:7/10/2014)... researchers have observed the fractional quantum Hall effect in ... matter can be tuned by an electric field. ... when electrons confined to thin sheets are exposed to ... behavior where thousands of individual electrons behave as a ... effect is well established, many details of this collective ...
Breaking Biology Technology:Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Sensitive detection method may help impede illicit nuclear trafficking 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3
... North ... America, DEERFIELD, Ill., ... Cartago, Costa Rica has been,recognized with the 2008 Shingo Prize for Operational ... North America,-- is being honored for its achievements in driving higher quality ...
... announced today it,submitted to the U.S. Food & ... Application (BLA) for motavizumab, an investigational,monoclonal antibody (MAb) ... supported by clinical trial data from more than ... of serious disease,caused by respiratory syncytial virus (RSV) ...
... Unique and Innovative Formulation Available Without a ... Prescription ... today announced the,launch of PSORENT, a clinically proven, steroid-free, ... which has,proven efficacy against psoriasis symptoms, in a novel, ...
Cached Biology Technology:Baxter's Costa Rica Facility Recognized With Shingo Prize for Excellence in Manufacturing 2MedImmune Submits Biologics License Application to FDA for Motavizumab 2MedImmune Submits Biologics License Application to FDA for Motavizumab 3NeoStrata(R) Announces the Launch of PSORENT(TM) Psoriasis Topical Treatment 2
(Date:7/11/2014)... researchers from The Chinese University of Hong Kong, BGI ... soybean linked to salt tolerance, with implication for improving ... study published online in Nature Communications provides ... crop improvement. , Soybean is an important crop for ... soybeans have less genetic diversities than their wild counterparts. ...
(Date:7/11/2014)... Researchers have pioneered a revolutionary new way to ... Virtual Finger, allows scientists to move through digital ... using the flat surface of their computer screens. ... orders of magnitude more efficient, saving time, money ... areas of experimental biology. The software and its ...
(Date:7/11/2014)... cannabinoid receptor type 1 can inhibit voltage-gated ... reduce neurotransmitter release. However, some scholars demonstrated ... extracellular Ca2+ influx and increase neurotransmitter release. ... Hospital Affiliated to Tongji Medical College, Huazhong ... whole cell voltage-clamp and calcium imaging in ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... for benefiting degenerative diseases, and do so by invoking ... manner compatible with clinical use (i.e., without animal feeder ... were a few of a number of conclusions arrived ... Snyder, M.D., Ph.D., and spearheaded by a member of ...
... ability to discern one sex from another may depend ... nerve cells, and the number of receptors is controlled ... Illinois at Chicago researchers have found. , Everything from ... illnesses such as amyotrophic lateral sclerosis, muscular dystrophy, post-traumatic ...
... the first large-scale study to evaluate a candidate HIV ... study collaborators in the United States and South Africa. ... five sites throughout South Africa and is expected to ... of the HIV Vaccine Trials Network (HVTN), which is ...
Cached Biology News:Stem cells act through multiple mechanisms to benefit mice with neurodegenerative disease 2Stem cells act through multiple mechanisms to benefit mice with neurodegenerative disease 3Stem cells act through multiple mechanisms to benefit mice with neurodegenerative disease 4Stem cells act through multiple mechanisms to benefit mice with neurodegenerative disease 5Bisexual fruit flies show new role for neurochemical 2Africa's first large-scale HIV vaccine study launches 2Africa's first large-scale HIV vaccine study launches 3Africa's first large-scale HIV vaccine study launches 4